First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial).
Watabe T, Mukai K, Naka S, Sasaki H, Kamiya T, Hayakawa T, Fukuhara A, Takano T, Shirakami Y, Ooe K, Shigeno S, Okamura S, Masumura K, Hida E, Haba H, Toyoshima A, Isohashi K, Shimomura I, Tomiyama N.
Watabe T, et al. Among authors: shigeno s.
J Nucl Med. 2025 Dec 3;66(12):1941-1947. doi: 10.2967/jnumed.125.270810.
J Nucl Med. 2025.
PMID: 40998730
Free PMC article.
Clinical Trial.